MarginsXMarginsX
Home › Markets › Health Care › AGMB

AgomAb Therapeutics NV (AGMB)

AGMB trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$5.97
-6.13% on the day
Market cap
$294.0M
Micro cap
Revenue
Foreign filer: no machine-readable annual figure in SEC data
Net income
Foreign filer: no machine-readable annual figure in SEC data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerAGMB on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryBelgium
IPO year2026
SEC CIK0002020932
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inBelgium

Financials

Foreign filer: no machine-readable annual figure in SEC data.

Warning signs

Cash runway
20.0 months
$95.5M cash at December 31, 2025
Share count, 1 year
See the dilution note
Going-concern doubt
No
20-F filed April 23, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Based on the above and the actions the Company has taken, management has concluded that the substantial doubt about its ability to continue as a going concern has been alleviated beyond 12 months from issuance of these financial statements, and these financial statements have been prepared on a going concern basis."
20-F 2026-04-23
Cash and burn$95.5M cash; operating cash flow -$14.3M a quarter.Report 2025-12-31
Shares outstanding34,167,168 (2025-12-31). the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers Reviseurs d'Entreprises, Diegem, BelgiumPCAOB Form AP 2026-05-04
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
Not filed-$69.1M-$57.2M$95.5MNo debt tagsNeeds four quarters20-F 2026-04-23

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B42026-02-06
Latest annual report
FORM 20-F
20-F2026-04-23
Latest quarterly / interim
FORM 6-K
6-K2026-10-13

Source: SEC EDGAR submissions feed, 51 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-16.8%
1 month-27.8%
3 months-54.4%
Year to dateNot enough price history
1 yearNot enough price history
From 52-week high-64.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
TRXBTRex Bio Inc.$10.77-21.21%$295.6M
EIKNEikon Therapeutics Inc.$5.38-9.95%$291.8M
SCTXScribe Therapeutics Inc.$15.37-6.05%$291.1M
IPSCCentury Therapeutics Inc.$1.64-0.61%$297.8M
XFORX4 Pharmaceuticals Inc.$2.83-9.29%$289.0M
EDITEditas Medicine Inc.$1.87-13.82%$288.6M
KYTXKyverna Therapeutics Inc.$4.76-5.74%$300.9M
AUTLAutolus Therapeutics plc American Depositary Share$1.14-2.56%$303.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier